Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,455,008
  • Shares Outstanding, K 83,133
  • Annual Sales, $ 434,250 K
  • Annual Income, $ -606,640 K
  • 60-Month Beta 0.68
  • Price/Sales 8.03
  • Price/Cash Flow N/A
  • Price/Book 25.49
Trade RARE with:

Options Overview Details

View History
  • Implied Volatility 45.45% ( -4.08%)
  • Historical Volatility 47.18%
  • IV Percentile 12%
  • IV Rank 14.01%
  • IV High 110.63% on 04/12/24
  • IV Low 34.83% on 12/22/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 16
  • Volume Avg (30-Day) 358
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 10,966
  • Open Int (30-Day) 11,593

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.63
  • Number of Estimates 11
  • High Estimate -1.32
  • Low Estimate -1.89
  • Prior Year -2.25
  • Growth Rate Est. (year over year) +27.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.00 +0.54%
on 05/08/24
52.56 -21.58%
on 04/11/24
-9.34 (-18.47%)
since 04/09/24
3-Month
41.00 +0.54%
on 05/08/24
54.56 -24.45%
on 03/01/24
-5.51 (-11.79%)
since 02/09/24
52-Week
31.52 +30.77%
on 10/24/23
54.98 -25.03%
on 06/06/23
-5.85 (-12.43%)
since 05/09/23

Most Recent Stories

More News
Ultragenyx: Q1 Earnings Snapshot

Ultragenyx: Q1 Earnings Snapshot

RARE : 41.22 (-0.82%)
Ultragenyx: Q4 Earnings Snapshot

Ultragenyx: Q4 Earnings Snapshot

RARE : 41.22 (-0.82%)
Ultragenyx: Q3 Earnings Snapshot

Ultragenyx: Q3 Earnings Snapshot

RARE : 41.22 (-0.82%)
Ultragenyx: Q2 Earnings Snapshot

Ultragenyx: Q2 Earnings Snapshot

RARE : 41.22 (-0.82%)
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

DNLI : 18.67 (-1.22%)
RARE : 41.22 (-0.82%)
SRPT : 132.30 (-0.21%)
PFE : 28.18 (-0.32%)
EXEL : 21.76 (+0.79%)
MRNA : 122.69 (+0.66%)
UTHR : 266.05 (+1.90%)
BIIB : 222.75 (+1.38%)
SNY : 48.69 (-2.81%)
LLY : 771.55 (-0.45%)
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates

Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.

REGN : 968.00 (+1.28%)
RARE : 41.22 (-0.82%)
APTX : 0.0960 (+3.11%)
ETNB : 9.11 (+0.89%)
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -18.27% and 4.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

RARE : 41.22 (-0.82%)
THMO : 0.6862 (-1.97%)
Ultragenyx: Q1 Earnings Snapshot

Ultragenyx: Q1 Earnings Snapshot

RARE : 41.22 (-0.82%)
Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue Estimates

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of -7.94% and 35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ALLO : 2.86 (+3.62%)
RARE : 41.22 (-0.82%)
Will Zymeworks Inc. (ZYME) Report Negative Earnings Next Week? What You Should Know

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZYME : 9.23 (+1.88%)
RARE : 41.22 (-0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 42.87
2nd Resistance Point 42.47
1st Resistance Point 41.85
Last Price 41.22
1st Support Level 40.83
2nd Support Level 40.43
3rd Support Level 39.81

See More

52-Week High 54.98
Fibonacci 61.8% 46.02
Fibonacci 50% 43.25
Last Price 41.22
Fibonacci 38.2% 40.48
52-Week Low 31.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar